Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | When to consider an escalation approach for MS treatment

Dalia Rotstein, MD, MPH, St. Michael’s Hospital and the University of Toronto, Toronto, Canada, discusses the use of escalation therapy for newly diagnosed multiple sclerosis (MS) patients. An escalation approach is not appropriate for every patient, and a key step when considering the best strategy is prognostication at baseline. When a patient is diagnosed with MS, it is important to consider their prognostic factors, including demographic, clinical, and radiological features. An escalation approach should be considered when patients lack poor prognostic factors. It is also crucial to understand the patient’s preferences regarding treatment risks, route of administration, and adverse events. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


DLR has received research support from the MS Society of Canada, CMSC, University of Toronto Division of Neurology, and Roche Canada. DLR has received speaker or consulting fees from Alexion, Biogen, EMD Serono, Novartis, Roche and Sanofi Aventis.